Modified lentiviral globin gene therapy for pediatric β
CD34(+) cell
HSPC
gene addition
gene therapy
globin
insulator
lentivirus
red blood cell
single-cell DNA sequencing
β(0)/β(0) thalassemia
Journal
Cell stem cell
ISSN: 1875-9777
Titre abrégé: Cell Stem Cell
Pays: United States
ID NLM: 101311472
Informations de publication
Date de publication:
10 May 2024
10 May 2024
Historique:
received:
28
07
2023
revised:
24
01
2024
accepted:
24
04
2024
medline:
18
5
2024
pubmed:
18
5
2024
entrez:
17
5
2024
Statut:
aheadofprint
Résumé
β
Identifiants
pubmed: 38759653
pii: S1934-5909(24)00175-9
doi: 10.1016/j.stem.2024.04.021
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests Y.C. is a co-founder and advisor of BDgene Therapeutics. S. Ling and X.W. filed two patents related to this work (“Lentiviral vector applicable to gene therapy of thalassemia and sickle anemia,” ZL201910824134.8, September 2, 2019, China; and “Lentiviral vector applicable to gene therapy of thalassemia and sickle anemia,” ZL202210013838.9, January 6, 2022, China).